The experiment, which is a component of NHS England’s new Cancer Vaccine Launch Pad (CVLP), has been signed up by 30 trusts in England, including the Royal Wolverhampton Trust (RWT).
The goal of RWT is to refer two patients a month to the program.
The trust’s Sarah Glover described it as an innovative and stimulating initiative that gave patients the chance to participate in cutting-edge cancer treatment trials.
The process of developing vaccinations involves analyzing a patient’s tumor to find mutations unique to their particular cancer.
Doctors use this data to develop an experimental, personalized “cancer vaccine.”
They are intended to trigger an immunological reaction that could stop cancer from spreading.
The biopharmaceutical firms BioNTech and Genentech are developing the vaccinations; they are currently undergoing trials and have not yet received regulatory approval.
